Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs expected health outcomes, this analysis evaluated long-term cost-effectiveness introducing to standard-of-care T1D treatment (standard care) from societal perspective. Clinical outcomes (in 2018 krona, SEK) were projected over patients' lifetimes using IQVIA CORE Diabetes...

Background and aims: Effective glycemic control is the cornerstone of successful type 2 diabetes management. However, many patients fail to reach targets, therapeutic inertia (failure intensify therapy address poor in a timely manner) has been widely reported. The aim present study was evaluate economic burden associated with diabetes-related complications due for UK.Methods: A validated long-term model (IQVIA CORE Diabetes Model) used project cost outcomes UK population diabetes, based on...

The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue semaglutide 14 mg was associated with significantly greater reductions in glycated haemoglobin (HbA1c) versus a sodium-glucose cotransporter-2 inhibitor (empagliflozin 25 mg), dipeptidyl peptidase-4 (sitagliptin 100 mg) and an injectable GLP-1 (liraglutide 1.8 mg). aim of present analysis to assess long-term cost-effectiveness each these comparators UK setting.Analyses were...

Glucagon-like peptide-1 (GLP-1) receptor agonists are appealing as glucose-lowering therapy for individuals with type 2 diabetes mellitus (T2DM) they also reduce body weight and associated low rates of hypoglycaemia. This analysis assessed the long-term cost-effectiveness semaglutide 0.5 1 mg vs dulaglutide 1.5 (two once-weekly GLP-1 agonists) from a UK healthcare payer perspective, based on head-to-head SUSTAIN 7 trial, to inform decision making.Long-term outcomes were projected using IQVIA...

Objective Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed cost-effectiveness once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) receptor agonist) versus insulin glargine U100 (the most commonly used basal insulin) dulaglutide (an alternative GLP-1 agonist), from a societal perspective in Netherlands. Research design methods IQVIA...

Effective glycemic control can reduce the risk of serious micro- and macrovascular complications in type 2 diabetes. However, many patients fail to reach targets due partly low efficacy adverse effects treatment such as hypoglycemia or weight gain.To evaluate short-term cost-effectiveness liraglutide versus sitagliptin, terms cost per patient reaching a glycated hemoglobin (HbA1c) target with no gain after 52 weeks, based on recently published trial. Data were taken from 52-week randomized,...

Aims: The efficacy and safety of oral semaglutide, the first glucagon-like peptide-1 (GLP-1) receptor agonist developed for administration treatment type 2 diabetes, was evaluated in PIONEER clinical trial program, a recently published network meta-analysis allowed comparison with further injectable GLP-1 agonists. present study aimed to assess short-term cost- effectiveness semaglutide 14 mg versus subcutaneous once-weekly dulaglutide 1.5 mg, exenatide twice-daily 10 µg, once-daily...

Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes (T2D) that has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight versus GLP-1 receptor agonists dulaglutide, exenatide extended-release (ER), liraglutide lixisenatide SUSTAIN trial program network meta-analysis (NMA). The aim present study was to assess long-term cost-effectiveness all available Denmark, using clinically orientated approach....

Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 for treatment patients with type mellitus inadequate glycaemic control on metformin monotherapy from payer perspective in UK. Outcomes were projected over patient lifetimes using IQVIA CORE Diabetes Model. Baseline cohort...

Glucagon-like peptide-1 (GLP-1) receptor agonists represent highly efficacious treatment options for type 2 diabetes. Liraglutide was amongst the first authorised use in 2010, but once-weekly semaglutide represents most GLP-1 analogue currently available The aim of present analysis therefore to evaluate long-term cost-effectiveness 1 mg versus liraglutide 1.8 with a lowered acquisition cost UK, as potentially lower formulations may soon be developed. Outcomes were projected over patients’...

Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 agonist currently available and has been associated with reductions in glycated hemoglobin body weight versus once-daily injectable liraglutide after 52 weeks PIONEER 4 clinical trial. As lower-cost formulations have recently developed, present analysis evaluated long-term cost-effectiveness of oral 14 mg 1.8 at lower...

To evaluate the annual cost-utility of insulin degludec compared with glargine in patients with: type 1 diabetes (T1D), 2 receiving basal-only therapy (T2D-BOT), and basal-bolus (T2B-BB) Sweden.A model was programmed Microsoft Excel to clinical economic outcomes. The trials were designed as treat-to-target, doses adjusted order achieve similar glycemic control between treatments, thus long-term modeling is not meaningful. Basal bolus doses, incidence hypoglycemic events, frequency...

Metformin is the first-line therapy for most patients with type 2 diabetes, but majority require treatment intensification at some stage due to progressive nature of disease. The 1860-LIRA-DPP-4 trial showed that liraglutide exhibited greater improvements compared sitagliptin in glycated hemoglobin and body mass index diabetes inadequately controlled on metformin monotherapy. As a follow-up previously published cost-effectiveness analysis 1.2 mg versus Spain, aim this was compare long-term...

Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for treatment of type 2 diabetes, and has been evaluated in PIONEER clinical trial program. These trials assessed proportions patients achieving single composite endpoints, encompassing glycemic control [defined terms glycated hemoglobin (HbA1c)], weight loss, hypoglycemia. The present study cost with oral versus empagliflozin, sitagliptin, liraglutide US. Four endpoints were evaluated: (1) HbA1c ≤...

Once-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than GLP-1 RA once-daily liraglutide 1.2 SUSTAIN 10 trial. The present analysis aimed to evaluate long-term cost-effectiveness once-weekly versus from UK healthcare payer perspective. Long-term outcomes were projected using IQVIA CORE Diabetes Model (version 9.0),...

Treatment with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, which target the incretin axis, has potential to improve glycemic control in type 2 diabetes patients without weight gain associated traditional therapies. To evaluate relative cost-effectiveness of therapies, present study aimed compare long-term clinical cost implications liraglutide sitagliptin Spain.

Background and aims: IDegLira, a fixed ratio combination of insulin degludec glucagon-like peptide-1 receptor agonist liraglutide, utilizes the complementary mechanisms action these two agents to improve glycemic control with low risk hypoglycemia avoidance weight gain. The aim present analysis was assess long-term cost-effectiveness IDegLira vs liraglutide added basal insulin, for patients type 2 diabetes not achieving on in US setting.Methods: Projections lifetime costs clinical outcomes...

The present study aimed to compare the projected long-term clinical and cost implications associated with liraglutide, sitagliptin glimepiride in patients type 2 diabetes mellitus failing achieve glycemic control on metformin monotherapy France.Clinical input data for modeling analysis were taken from two randomized, controlled trials (LIRA-DPP4 LEAD-2). Long-term (patient lifetime) projections of outcomes direct costs (2013 Euros; €) made using a validated computer simulation model...

In patients with inflammatory bowel disease (IBD), iron deficiency anaemia (IDA) can impair quality of life and increase healthcare costs. Treatment options for IDA-associated IBD include oral intravenous formulations (such as ferric carboxymaltose [FCM], derisomaltose [FD, previously known isomaltoside 1000], sucrose [IS]). The present analysis compared the cost-effectiveness FCM versus FD, IS, sulfate in terms additional cost per responder UK setting.Cost-effectiveness was calculated...